% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • ahhaha2 ahhaha2 Nov 3, 2012 12:28 AM Flag

    The CC, Q&A, Jeffries

    Biren Amin - Jefferies & Company, Inc., Research Division

    First of all, on the C-MAP patients that converted, what's the average treatment duration of these 110 patients?

    Second, on Onyx 360, it seems like it's a pretty generous co-pay assistance program. So I just want to see a percentage of patients treated so far that have benefited from the co-pay systems.
    And third, on Nexavar, RESILIENCE, is it still on track for enrollment finishing in first half of '13?



    Helen I. Torley

    Now I'm looking at Barbara. In terms of the duration of therapy for the C-MAP, Barb, I don't know if you get any specifics as to how long that group of patients have been on. I would imagine it was a shorter duration because it was probably the more recently enrolled patients. But, Barb, any specifics?

    Barbara Klencke

    Well, I will just say we don't have specifics today. But the trial of C-MAP was conducted within development organization as a clinical trial. And of course, we will collect all of that data, and we will be reporting that data. Much of the patients who were still on therapy, of course, at the time that they convert to commercial drug are then off trial. So we'll have some data in the future, but not a lot. I expected that it'll be very clear -- clearly, the patients that came into the C-MAP, which was rigorously defined exactly like the 003-A1 study, are likely to reflect the overall 001A -- 003-A1 clinical study pretty closely.


    Where the treatment duration was, 4.5 months, on average. So just to remind everyone. And then while you've got the floor, Barb, if you could address the RESILIENCE breast cancer trial?

    Barbara Klencke

    That's right. It is on track. The enrollment is going well. We're a very steady state right now with a projection of completion on the first half of 2013.
    N. Anthony Coles - Chief Executive Officer, President and Director

    Okay. And the thyroid in this quarter before the end of the year.

    Barbara Klencke



    Very good. And then, Helen, do you want to talk a little bit about how Onyx 360 looks?

    Helen I. Torley - Chief Commercial officer and Executive Vice President

    Yes. Well, we've seen some robust enrollment in Onyx 360 to date. The commonest reasons for patient signing up for Onyx 360 are insurance verification, co-pay assistance, as you mentioned, but also for referral to transportation assistance. All of these 3, I would say co-pay assistance is the minority of patients at this time that -- of the launch.